Home/Pipeline/PMN310

PMN310

Alzheimer's Disease

Phase 1bActive - PRECISE-AD trial fully enrolled

Key Facts

Indication

Alzheimer's Disease

Phase

Phase 1b

Status

Active - PRECISE-AD trial fully enrolled

Company

ProMIS Neurosciences

About ProMIS Neurosciences

ProMIS Neurosciences is dedicated to developing precision antibody therapies for neurodegenerative diseases by selectively targeting toxic misfolded protein oligomers. Its core achievement is the EpiSelect™ computational discovery platform, which has generated a pipeline of candidates, including PMN310 for Alzheimer's disease, now in a Phase 1b trial. The company's strategy is to demonstrate a differentiated safety and efficacy profile by sparing non-toxic protein forms, aiming to advance directly into registrational studies. A recent $175 million financing provides a cash runway through 2027 to execute this plan.

View full company profile

Therapeutic Areas

Alzheimer's Disease Amyotrophic Lateral Sclerosis Parkinson's Disease Multiple System Atrophy Frontotemporal Dementia

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
ALZN002	Alzamend Neuro	Preclinical	Research
P021	Phanes Biotech	Preclinical	Active
PB43D	Phanes Biotech	Preclinical	Active
UB-311	Vaxxinity	Phase 2	Active
Lecanemab	BioArctic	Launched	Active (Commercial)
BAN2401	BioArctic	Preclinical	Active
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
MK-6240 (florquinitau)	Lantheus Medical Imaging	Regulatory Filing	Filed
NAV-4694 (flutafuranol)	Lantheus Medical Imaging	Phase 3	Active
LNTH-2620/PI-2620	Lantheus Medical Imaging	Phase 3	Recruiting
itMSCs	Stemedica Cell Technologies	Clinical Development	Active